ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
ACT001 alleviates sepsis-induced acute lung injury by downregulating PANoptosis via the JAK2/STAT3 pathway.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveSepsis-induced acute respiratory distress syndrome (ARDS) is associated with high mortality and limited therapeutic options. ACT001, a novel derivative with anti-inflammatory properties, has shown potential for mitigating lung injury; however, its underlying mechanisms remain elusive. This study investigates the protective effects of ACT001 against sepsis-induced acute lung injury (ALI) and explores whether these effects involve the regulation of PANoptosis via the JAK2/STAT3 signaling pathway.
methodsUsing lipopolysaccharide (LPS)-stimulated A549 alveolar epithelial cells and a cecal ligation and puncture (CLP)-induced septic rat model, we evaluated the effects of ACT001. Assessments included CCK-8 viability assays, survival analysis, histopathological examination (H&E staining), and ELISA for inflammatory cytokines (IL-6, TNF-α, IL-1β). Immunofluorescence and Western blotting were performed to detect PANoptosis markers (ZBP1, cleaved caspase-3, p-MLKL, N-GSDMD) and JAK2/STAT3 pathway proteins. The JAK2 inhibitor AG490 was employed to validate the involvement of this pathway.
resultsACT001 significantly improved the viability of LPS-stimulated A549 cells and extended the survival of septic rats. It attenuated alveolar histopathological injury, reduced inflammatory cell infiltration, and decreased plasma cytokine levels. Molecular analyses revealed that ACT001 suppressed the expression of PANoptosis markers (ZBP1, cleaved caspase-3, p-MLKL, N-GSDMD) and inhibited JAK2/STAT3 phosphorylation in both models. Notably, treatment with AG490 reproduced these protective effects, supporting the mechanistic role of the JAK2/STAT3 pathway.
conclusionThis study demonstrates that ACT001 mitigates sepsis-induced lung injury, likely by inhibiting PANoptosis through the suppression of the JAK2/STAT3 pathway. These findings provide new insights into the interplay between inflammatory cell death and JAK/STAT signaling, suggesting that ACT001 warrants further investigation as a potential therapeutic agent for sepsis-related ARDS.
Indexed as
Identifiers
41917427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.